View ValuationStarsource Multitrade 将来の成長Future 基準チェック /06現在、 Starsource Multitradeの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 31Full year 2026 earnings released: ₹79.03 loss per share (vs ₹2.28 profit in FY 2025)Full year 2026 results: ₹79.03 loss per share (down from ₹2.28 profit in FY 2025). Revenue: ₹5.50m (down 11% from FY 2025). Net loss: ₹118.5m (down ₹122.0m from profit in FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 171 percentage points per year, which is a significant difference in performance.お知らせ • May 25Starsource Multitrade Limited to Report Q4, 2026 Results on May 29, 2026Starsource Multitrade Limited announced that they will report Q4, 2026 results on May 29, 2026Reported Earnings • Feb 14Third quarter 2026 earnings released: ₹0.58 loss per share (vs ₹1.17 loss in 3Q 2025)Third quarter 2026 results: ₹0.58 loss per share (improved from ₹1.17 loss in 3Q 2025). Net loss: ₹865.1k (loss narrowed 51% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 165 percentage points per year, which is a significant difference in performance.お知らせ • Feb 09Starsource Multitrade Limited to Report Q3, 2026 Results on Feb 12, 2026Starsource Multitrade Limited announced that they will report Q3, 2026 results on Feb 12, 2026お知らせ • Nov 10Starsource Multitrade Limited to Report Q2, 2026 Results on Nov 13, 2025Starsource Multitrade Limited announced that they will report Q2, 2026 results on Nov 13, 2025New Risk • Oct 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹198.0m market cap, or US$2.23m).お知らせ • Sep 26+ 2 more updatesChemo Pharma Laboratories Limited Announces Changes to Its BoardChemo Pharma Laboratories Limited Limited announced in the 83rd annual general meeting held on September 24, 2025, the company approved the appointment and regularization of Ms. Sarvagya Goel as independent director of the company, appointment and regularization of Ms. Shiply Chopra as Independent Director of the company, appointment and regularization of Ms. Simran Utsav Trivedi as independent director of the company and appointment and regularization of Mr. Utsav trivedi as Executive director. Appointment and regularization of ruchit Mehta as Managing director.New Risk • Sep 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹187.0m market cap, or US$2.12m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 47% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$39k). Market cap is less than US$10m (₹202.4m market cap, or US$2.31m).お知らせ • Aug 13Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025, at 16:00 Indian Standard Time.お知らせ • Aug 05Chemo Pharma Laboratories Limited to Report Q1, 2026 Results on Aug 12, 2025Chemo Pharma Laboratories Limited announced that they will report Q1, 2026 results on Aug 12, 2025Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹146, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 306% over the past three years.お知らせ • May 14Chemo Pharma Laboratories Limited to Report Q4, 2025 Results on May 29, 2025Chemo Pharma Laboratories Limited announced that they will report Q4, 2025 results on May 29, 2025お知らせ • Apr 23Chemo Pharma Laboratories Limited Approves the Appointment of Bhawna Rajput as Company Secretary and Compliance Officer, Effective 16 April, 2025Chemo Pharma Laboratories Limited announced that at the board meeting held on April 16, 2025, approved the appointment of CS Bhawna Rajput as Company Secretary and Compliance Officer of the Company with effect from 16 April, 2025.お知らせ • Apr 08+ 2 more updatesChemo Pharma Laboratories Limited Announces Board and Executive ResignationsChemo Pharma Laboratories Limited announced the resignation of Mr. Bhavin Sheth from the position of Executive Director of the Company; resignation of Shri. Ashok Somani from the position of Executive Director of the Company; resignation of Mrs. Shanta Somani from the position of Non-Executive Director of the Company; resignation of Shri. Mathura Prasad Sharma, from the position of Directorship of the Company in the category of Non-Executive Independent Director; resignation of Shri Toby Antony from the position of Directorship of the Company in the category of Non- Executive Independent Director; resignation of Shri Nandkumar Pareek from the position of Directorship of the Company in the category of Non-Executive Independent Director; resignation of Mrs. Unnatti Jain, from the position of Company Secretary and Compliance Officer of the Company.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹63.05, the stock trades at a trailing P/E ratio of 24.2x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 45% over the past three years.New Risk • Jan 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 38% Last year net profit margin: 90% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (₹10m revenue, or US$119k). Market cap is less than US$10m (₹127.7m market cap, or US$1.48m). Minor Risk Profit margins are more than 30% lower than last year (38% net profit margin).お知らせ • Jan 13Chemo Pharma Laboratories Limited to Report Q3, 2025 Results on Jan 27, 2025Chemo Pharma Laboratories Limited announced that they will report Q3, 2025 results on Jan 27, 2025Valuation Update With 7 Day Price Move • Dec 19Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to ₹98.45, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 234% over the past three years.Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹93.82, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 206% over the past three years.Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹82.72, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 172% over the past three years.お知らせ • Oct 15Chemo Pharma Laboratories Limited to Report Q2, 2025 Results on Oct 28, 2024Chemo Pharma Laboratories Limited announced that they will report Q2, 2025 results on Oct 28, 2024Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 31%After last week's 31% share price gain to ₹86.07, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 28x in the Diversified Financial industry in India. Total returns to shareholders of 246% over the past three years.New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹17m revenue, or US$204k). Market cap is less than US$10m (₹107.8m market cap, or US$1.28m). Minor Risk Share price has been volatile over the past 3 months (7.9% average weekly change).Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹78.99, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 220% over the past three years.Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹72.50, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 194% over the past three years.お知らせ • Jul 10+ 1 more updateChemo Pharma Laboratories Limited, Annual General Meeting, Sep 23, 2024Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 23, 2024, at 16:00 Indian Standard Time. Location: 5-kumud apartment co.op.hsg.soc.ltd, karnik road, chikan ghar, kalyan - 421301, thane IndiaValuation Update With 7 Day Price Move • Jul 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹58.00, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 124% over the past three years.お知らせ • May 12Chemo Pharma Laboratories Limited to Report Q4, 2024 Final Results on May 27, 2024Chemo Pharma Laboratories Limited announced that they will report Q4, 2024 final results on May 27, 2024Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹63.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 24x in the Diversified Financial industry in India. Total returns to shareholders of 255% over the past three years.お知らせ • Jan 10Chemo Pharma Laboratories Limited to Report Q3, 2024 Results on Jan 29, 2024Chemo Pharma Laboratories Limited announced that they will report Q3, 2024 results on Jan 29, 2024Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹75.63, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 119% over the past three years.Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹57.37, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 190% over the past three years.Valuation Update With 7 Day Price Move • Oct 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹37.15, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 106% over the past three years.Board Change • Sep 02Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Nand Pareek was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 30+ 2 more updatesChemo Pharma Laboratories Limited to Report Fiscal Year 2024 Results on May 30, 2024Chemo Pharma Laboratories Limited announced that they will report fiscal year 2024 results on May 30, 2024New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹11m revenue, or US$134k). Market cap is less than US$10m (₹57.5m market cap, or US$693.4k). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹34.81, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 404% over the past three years.お知らせ • Jul 15+ 1 more updateChemo Pharma Laboratories Limited to Report Q1, 2024 Results on Jul 27, 2023Chemo Pharma Laboratories Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Jul 27, 2023お知らせ • May 26Chemo Pharma Laboratories Limited Announces Executive ChangesChemo Pharma Laboratories Limited announced at the board meeting held on May 24, 2023 that the company approved Appointment of Unnati Jain, Company Secretary and Compliance Officers of the Company. Ms. Unnatti Jain aged 32 years is a qualified Company Secretary and a Bachelor of Commerce Graduate. She has worked with public and private limited companics as a Company Secretary. She has vast experience in the field of Companies Act, SEBI Rules and Regulation, LODR and related work. Her knowledge and experience in the legal and compliance field will help the company in a significant way. Mr. Ashok Somani as ceased to Compliance Officer of the Company.お知らせ • May 17Chemo Pharma Laboratories Limited to Report Q4, 2023 Results on May 24, 2023Chemo Pharma Laboratories Limited announced that they will report Q4, 2023 results at 3:30 PM, Indian Standard Time on May 24, 2023Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹40.00, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 21x in the Diversified Financial industry in India. Total returns to shareholders of 433% over the past three years.お知らせ • Jan 05Chemo Pharma Laboratories Limited to Report Q3, 2023 Results on Jan 31, 2023Chemo Pharma Laboratories Limited announced that they will report Q3, 2023 results on Jan 31, 2023お知らせ • Dec 27Chemo Pharma Laboratories Limited Announces Management ChangesChemo Pharma Laboratories Limited informed that the Board of Directors of the Company at their meeting held on December 26, 2022, have discussed and approved the resignation of Ms. Neha Vora as a Company Secretary and Compliance Officer of the Company with effect from December 15, 2022 and approved the appointment of Mr. Ashok Somani, Director as Compliance Officer of the Company with effect from December 26, 2022.お知らせ • Dec 16Chemo Pharma Laboratories Limited Announces Resignation of Neha Vora as Company Secretary / Compliance OfficerChemo Pharma Laboratories Limited informed that Ms. Neha Vora, an Associate Member of the Institute of Company Secretaries of India having membership no.A30747, has resigned from the position of the Company Secretary & Compliance Officer of the Company with effect from end of the office hours on December 15, 2022.Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹41.55, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 20x in the Diversified Financial industry in India. Total returns to shareholders of 560% over the past three years.お知らせ • Oct 14Chemo Pharma Laboratories Limited to Report Q2, 2023 Results on Oct 20, 2022Chemo Pharma Laboratories Limited announced that they will report Q2, 2023 results on Oct 20, 2022お知らせ • Jul 21+ 1 more updateChemo Pharma Laboratories Limited, Annual General Meeting, Sep 08, 2022Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 08, 2022, at 16:00 Indian Standard Time. Location: 5-Kumud Apartment Co. op. Hsg. Soc. Ltd. Karnik Road, Chikan Ghar, Kalyan Thane IndiaValuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years.Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years.お知らせ • May 18Chemo Pharma Laboratories Limited to Report Q4, 2022 Results on May 27, 2022Chemo Pharma Laboratories Limited announced that they will report Q4, 2022 results on May 27, 2022Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹34.40, the stock trades at a trailing P/E ratio of 24.7x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹23.10, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 13x in the Diversified Financial industry in India. Total loss to shareholders of 35% over the past three years.お知らせ • Jan 29+ 1 more updateChemo Pharma Laboratories Limited Appoints Bhavin Sheth as Chief Executive OfficerChemo Pharma Laboratories Limited at its board meeting held on January 28, 2021 approved the appointment of Shri. Bhavin Sheth as Chief Executive Officer of the company.お知らせ • Jan 12Chemo Pharma Laboratories Limited to Report Q3, 2021 Results on Jan 28, 2021Chemo Pharma Laboratories Limited announced that they will report Q3, 2021 results on Jan 28, 2021Is New 90 Day High Low • Dec 28New 90-day high: ₹22.80The company is up 17% from its price of ₹19.43 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Diversified Financial industry, which is up 26% over the same period.Valuation Update With 7 Day Price Move • Dec 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹21.75, the stock is trading at a trailing P/E ratio of 12x, up from the previous P/E ratio of 10.5x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 49%.Valuation Update With 7 Day Price Move • Dec 10Market bids up stock over the past weekAfter last week's 17% share price gain to ₹16.95, the stock is trading at a trailing P/E ratio of 9.4x, up from the previous P/E ratio of 8x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 62%.お知らせ • Nov 12+ 1 more updateChemo Pharma Laboratories Limited Announces Sad Demise of Shreeniwas Somani, Chairman and Whole Time DirectorChemo Pharma Laboratories Limited announced sad demise of Shri. Shreeniwas Somani, Chairman and Whole Time Director of the Company who passed away on November 10, 2020 at night.お知らせ • Oct 10Chemo Pharma Laboratories Limited to Report Q2, 2021 Results on Oct 19, 2020Chemo Pharma Laboratories Limited announced that they will report Q2, 2021 results on Oct 19, 2020Is New 90 Day High Low • Sep 24New 90-day high: ₹17.97The company is up 165% from its price of ₹6.78 on 16 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is down 4.0% over the same period.お知らせ • Aug 11Chemo Pharma Laboratories Limited to Report Q1, 2021 Results on Aug 18, 2020Chemo Pharma Laboratories Limited announced that they will report Q1, 2021 results on Aug 18, 2020お知らせ • Jun 17Chemo Pharma Laboratories Limited to Report Q4, 2020 Results on Jun 26, 2020Chemo Pharma Laboratories Limited announced that they will report Q4, 2020 results on Jun 26, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Starsource Multitrade は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:506365 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20265-119-106-106N/A12/31/20254-121N/AN/AN/A9/30/20252-122-124-124N/A6/30/20253-117N/AN/AN/A3/31/202563-3-3N/A12/31/2024104N/AN/AN/A9/30/2024191299N/A6/30/20241711N/AN/AN/A3/31/2024181277N/A12/31/20231513N/AN/AN/A9/30/2023108-1-1N/A6/30/2023119N/AN/AN/A3/31/202330-7-7N/A12/31/202253N/AN/AN/A9/30/2022751616N/A6/30/202230N/AN/AN/A3/31/202286-3-3N/A12/31/202184N/AN/AN/A9/30/202152-4-4N/A6/30/202162N/AN/AN/A3/31/202153-4-4N/A12/31/202072N/AN/AN/A9/30/2020734848N/A6/30/202093N/AN/AN/A3/31/20201044848N/A12/31/2019116N/AN/AN/A9/30/2019116N/AN/AN/A6/30/2019104N/AN/AN/A3/31/201982N/A-55N/A12/31/201882N/AN/AN/A9/30/2018103N/AN/AN/A6/30/2018115N/AN/AN/A3/31/2018111N/A-17N/A12/31/20176045N/AN/AN/A9/30/20175742N/AN/AN/A6/30/20175642N/AN/AN/A3/31/20175647N/A64N/A12/31/20165-14N/AN/AN/A9/30/20165-14N/AN/AN/A6/30/20165-14N/AN/AN/A3/31/20165-14N/A-21N/A12/31/201552N/AN/AN/A9/30/201552N/AN/AN/A6/30/201552N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 506365の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 506365の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 506365の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 506365の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 506365の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 506365の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 16:24終値2026/06/10 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Starsource Multitrade Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 31Full year 2026 earnings released: ₹79.03 loss per share (vs ₹2.28 profit in FY 2025)Full year 2026 results: ₹79.03 loss per share (down from ₹2.28 profit in FY 2025). Revenue: ₹5.50m (down 11% from FY 2025). Net loss: ₹118.5m (down ₹122.0m from profit in FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 171 percentage points per year, which is a significant difference in performance.
お知らせ • May 25Starsource Multitrade Limited to Report Q4, 2026 Results on May 29, 2026Starsource Multitrade Limited announced that they will report Q4, 2026 results on May 29, 2026
Reported Earnings • Feb 14Third quarter 2026 earnings released: ₹0.58 loss per share (vs ₹1.17 loss in 3Q 2025)Third quarter 2026 results: ₹0.58 loss per share (improved from ₹1.17 loss in 3Q 2025). Net loss: ₹865.1k (loss narrowed 51% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 165 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 09Starsource Multitrade Limited to Report Q3, 2026 Results on Feb 12, 2026Starsource Multitrade Limited announced that they will report Q3, 2026 results on Feb 12, 2026
お知らせ • Nov 10Starsource Multitrade Limited to Report Q2, 2026 Results on Nov 13, 2025Starsource Multitrade Limited announced that they will report Q2, 2026 results on Nov 13, 2025
New Risk • Oct 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹198.0m market cap, or US$2.23m).
お知らせ • Sep 26+ 2 more updatesChemo Pharma Laboratories Limited Announces Changes to Its BoardChemo Pharma Laboratories Limited Limited announced in the 83rd annual general meeting held on September 24, 2025, the company approved the appointment and regularization of Ms. Sarvagya Goel as independent director of the company, appointment and regularization of Ms. Shiply Chopra as Independent Director of the company, appointment and regularization of Ms. Simran Utsav Trivedi as independent director of the company and appointment and regularization of Mr. Utsav trivedi as Executive director. Appointment and regularization of ruchit Mehta as Managing director.
New Risk • Sep 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$38k). Market cap is less than US$10m (₹187.0m market cap, or US$2.12m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
New Risk • Aug 14New major risk - Revenue and earnings growthEarnings have declined by 47% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (₹3.4m revenue, or US$39k). Market cap is less than US$10m (₹202.4m market cap, or US$2.31m).
お知らせ • Aug 13Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 24, 2025, at 16:00 Indian Standard Time.
お知らせ • Aug 05Chemo Pharma Laboratories Limited to Report Q1, 2026 Results on Aug 12, 2025Chemo Pharma Laboratories Limited announced that they will report Q1, 2026 results on Aug 12, 2025
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹146, the stock trades at a trailing P/E ratio of 56.1x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 306% over the past three years.
お知らせ • May 14Chemo Pharma Laboratories Limited to Report Q4, 2025 Results on May 29, 2025Chemo Pharma Laboratories Limited announced that they will report Q4, 2025 results on May 29, 2025
お知らせ • Apr 23Chemo Pharma Laboratories Limited Approves the Appointment of Bhawna Rajput as Company Secretary and Compliance Officer, Effective 16 April, 2025Chemo Pharma Laboratories Limited announced that at the board meeting held on April 16, 2025, approved the appointment of CS Bhawna Rajput as Company Secretary and Compliance Officer of the Company with effect from 16 April, 2025.
お知らせ • Apr 08+ 2 more updatesChemo Pharma Laboratories Limited Announces Board and Executive ResignationsChemo Pharma Laboratories Limited announced the resignation of Mr. Bhavin Sheth from the position of Executive Director of the Company; resignation of Shri. Ashok Somani from the position of Executive Director of the Company; resignation of Mrs. Shanta Somani from the position of Non-Executive Director of the Company; resignation of Shri. Mathura Prasad Sharma, from the position of Directorship of the Company in the category of Non-Executive Independent Director; resignation of Shri Toby Antony from the position of Directorship of the Company in the category of Non- Executive Independent Director; resignation of Shri Nandkumar Pareek from the position of Directorship of the Company in the category of Non-Executive Independent Director; resignation of Mrs. Unnatti Jain, from the position of Company Secretary and Compliance Officer of the Company.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹63.05, the stock trades at a trailing P/E ratio of 24.2x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 45% over the past three years.
New Risk • Jan 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 38% Last year net profit margin: 90% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (₹10m revenue, or US$119k). Market cap is less than US$10m (₹127.7m market cap, or US$1.48m). Minor Risk Profit margins are more than 30% lower than last year (38% net profit margin).
お知らせ • Jan 13Chemo Pharma Laboratories Limited to Report Q3, 2025 Results on Jan 27, 2025Chemo Pharma Laboratories Limited announced that they will report Q3, 2025 results on Jan 27, 2025
Valuation Update With 7 Day Price Move • Dec 19Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to ₹98.45, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 234% over the past three years.
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹93.82, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 206% over the past three years.
Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹82.72, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 29x in the Diversified Financial industry in India. Total returns to shareholders of 172% over the past three years.
お知らせ • Oct 15Chemo Pharma Laboratories Limited to Report Q2, 2025 Results on Oct 28, 2024Chemo Pharma Laboratories Limited announced that they will report Q2, 2025 results on Oct 28, 2024
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 31%After last week's 31% share price gain to ₹86.07, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 28x in the Diversified Financial industry in India. Total returns to shareholders of 246% over the past three years.
New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹17m revenue, or US$204k). Market cap is less than US$10m (₹107.8m market cap, or US$1.28m). Minor Risk Share price has been volatile over the past 3 months (7.9% average weekly change).
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹78.99, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 220% over the past three years.
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹72.50, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 194% over the past three years.
お知らせ • Jul 10+ 1 more updateChemo Pharma Laboratories Limited, Annual General Meeting, Sep 23, 2024Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 23, 2024, at 16:00 Indian Standard Time. Location: 5-kumud apartment co.op.hsg.soc.ltd, karnik road, chikan ghar, kalyan - 421301, thane India
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹58.00, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 31x in the Diversified Financial industry in India. Total returns to shareholders of 124% over the past three years.
お知らせ • May 12Chemo Pharma Laboratories Limited to Report Q4, 2024 Final Results on May 27, 2024Chemo Pharma Laboratories Limited announced that they will report Q4, 2024 final results on May 27, 2024
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹63.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 24x in the Diversified Financial industry in India. Total returns to shareholders of 255% over the past three years.
お知らせ • Jan 10Chemo Pharma Laboratories Limited to Report Q3, 2024 Results on Jan 29, 2024Chemo Pharma Laboratories Limited announced that they will report Q3, 2024 results on Jan 29, 2024
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹75.63, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 119% over the past three years.
Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹57.37, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 25x in the Diversified Financial industry in India. Total returns to shareholders of 190% over the past three years.
Valuation Update With 7 Day Price Move • Oct 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹37.15, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 27x in the Diversified Financial industry in India. Total returns to shareholders of 106% over the past three years.
Board Change • Sep 02Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Nand Pareek was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 30+ 2 more updatesChemo Pharma Laboratories Limited to Report Fiscal Year 2024 Results on May 30, 2024Chemo Pharma Laboratories Limited announced that they will report fiscal year 2024 results on May 30, 2024
New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹11m revenue, or US$134k). Market cap is less than US$10m (₹57.5m market cap, or US$693.4k). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹34.81, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 26x in the Diversified Financial industry in India. Total returns to shareholders of 404% over the past three years.
お知らせ • Jul 15+ 1 more updateChemo Pharma Laboratories Limited to Report Q1, 2024 Results on Jul 27, 2023Chemo Pharma Laboratories Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Jul 27, 2023
お知らせ • May 26Chemo Pharma Laboratories Limited Announces Executive ChangesChemo Pharma Laboratories Limited announced at the board meeting held on May 24, 2023 that the company approved Appointment of Unnati Jain, Company Secretary and Compliance Officers of the Company. Ms. Unnatti Jain aged 32 years is a qualified Company Secretary and a Bachelor of Commerce Graduate. She has worked with public and private limited companics as a Company Secretary. She has vast experience in the field of Companies Act, SEBI Rules and Regulation, LODR and related work. Her knowledge and experience in the legal and compliance field will help the company in a significant way. Mr. Ashok Somani as ceased to Compliance Officer of the Company.
お知らせ • May 17Chemo Pharma Laboratories Limited to Report Q4, 2023 Results on May 24, 2023Chemo Pharma Laboratories Limited announced that they will report Q4, 2023 results at 3:30 PM, Indian Standard Time on May 24, 2023
Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹40.00, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 21x in the Diversified Financial industry in India. Total returns to shareholders of 433% over the past three years.
お知らせ • Jan 05Chemo Pharma Laboratories Limited to Report Q3, 2023 Results on Jan 31, 2023Chemo Pharma Laboratories Limited announced that they will report Q3, 2023 results on Jan 31, 2023
お知らせ • Dec 27Chemo Pharma Laboratories Limited Announces Management ChangesChemo Pharma Laboratories Limited informed that the Board of Directors of the Company at their meeting held on December 26, 2022, have discussed and approved the resignation of Ms. Neha Vora as a Company Secretary and Compliance Officer of the Company with effect from December 15, 2022 and approved the appointment of Mr. Ashok Somani, Director as Compliance Officer of the Company with effect from December 26, 2022.
お知らせ • Dec 16Chemo Pharma Laboratories Limited Announces Resignation of Neha Vora as Company Secretary / Compliance OfficerChemo Pharma Laboratories Limited informed that Ms. Neha Vora, an Associate Member of the Institute of Company Secretaries of India having membership no.A30747, has resigned from the position of the Company Secretary & Compliance Officer of the Company with effect from end of the office hours on December 15, 2022.
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹41.55, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 20x in the Diversified Financial industry in India. Total returns to shareholders of 560% over the past three years.
お知らせ • Oct 14Chemo Pharma Laboratories Limited to Report Q2, 2023 Results on Oct 20, 2022Chemo Pharma Laboratories Limited announced that they will report Q2, 2023 results on Oct 20, 2022
お知らせ • Jul 21+ 1 more updateChemo Pharma Laboratories Limited, Annual General Meeting, Sep 08, 2022Chemo Pharma Laboratories Limited, Annual General Meeting, Sep 08, 2022, at 16:00 Indian Standard Time. Location: 5-Kumud Apartment Co. op. Hsg. Soc. Ltd. Karnik Road, Chikan Ghar, Kalyan Thane India
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years.
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹38.95, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 399% over the past three years.
お知らせ • May 18Chemo Pharma Laboratories Limited to Report Q4, 2022 Results on May 27, 2022Chemo Pharma Laboratories Limited announced that they will report Q4, 2022 results on May 27, 2022
Valuation Update With 7 Day Price Move • Jan 03Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹34.40, the stock trades at a trailing P/E ratio of 24.7x. Average trailing P/E is 19x in the Diversified Financial industry in India. Total returns to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹23.10, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 13x in the Diversified Financial industry in India. Total loss to shareholders of 35% over the past three years.
お知らせ • Jan 29+ 1 more updateChemo Pharma Laboratories Limited Appoints Bhavin Sheth as Chief Executive OfficerChemo Pharma Laboratories Limited at its board meeting held on January 28, 2021 approved the appointment of Shri. Bhavin Sheth as Chief Executive Officer of the company.
お知らせ • Jan 12Chemo Pharma Laboratories Limited to Report Q3, 2021 Results on Jan 28, 2021Chemo Pharma Laboratories Limited announced that they will report Q3, 2021 results on Jan 28, 2021
Is New 90 Day High Low • Dec 28New 90-day high: ₹22.80The company is up 17% from its price of ₹19.43 on 29 September 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Diversified Financial industry, which is up 26% over the same period.
Valuation Update With 7 Day Price Move • Dec 24Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹21.75, the stock is trading at a trailing P/E ratio of 12x, up from the previous P/E ratio of 10.5x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 49%.
Valuation Update With 7 Day Price Move • Dec 10Market bids up stock over the past weekAfter last week's 17% share price gain to ₹16.95, the stock is trading at a trailing P/E ratio of 9.4x, up from the previous P/E ratio of 8x. This compares to an average P/E of 13x in the Diversified Financial industry in India. Total return to shareholders over the past three years is a loss of 62%.
お知らせ • Nov 12+ 1 more updateChemo Pharma Laboratories Limited Announces Sad Demise of Shreeniwas Somani, Chairman and Whole Time DirectorChemo Pharma Laboratories Limited announced sad demise of Shri. Shreeniwas Somani, Chairman and Whole Time Director of the Company who passed away on November 10, 2020 at night.
お知らせ • Oct 10Chemo Pharma Laboratories Limited to Report Q2, 2021 Results on Oct 19, 2020Chemo Pharma Laboratories Limited announced that they will report Q2, 2021 results on Oct 19, 2020
Is New 90 Day High Low • Sep 24New 90-day high: ₹17.97The company is up 165% from its price of ₹6.78 on 16 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Diversified Financial industry, which is down 4.0% over the same period.
お知らせ • Aug 11Chemo Pharma Laboratories Limited to Report Q1, 2021 Results on Aug 18, 2020Chemo Pharma Laboratories Limited announced that they will report Q1, 2021 results on Aug 18, 2020
お知らせ • Jun 17Chemo Pharma Laboratories Limited to Report Q4, 2020 Results on Jun 26, 2020Chemo Pharma Laboratories Limited announced that they will report Q4, 2020 results on Jun 26, 2020